- $34.07bn
- $33.26bn
- $5.65bn
Annual income statement for ResMed, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 3,578 | 4,223 | 4,685 | 5,146 | 5,653 |
| Cost of Revenue | |||||
| Gross Profit | 2,024 | 2,356 | 2,655 | 3,053 | 3,452 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2,578 | 3,071 | 3,365 | 3,461 | 3,767 |
| Operating Profit | 1,000 | 1,152 | 1,320 | 1,685 | 1,887 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 960 | 1,102 | 1,265 | 1,678 | 1,919 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 779 | 898 | 1,021 | 1,401 | 1,523 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 779 | 898 | 1,021 | 1,401 | 1,523 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 779 | 898 | 1,021 | 1,401 | 1,523 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 5.31 | 6.09 | 7.38 | 10.1 | 11 |
| Dividends per Share |